Abstract
Fentanyl effervescent buccal tablets (FEBT) are designed to enhance the rate and efficiency of fentanyl absorption through the buccal mucosa. The results reported here represent the 3-month interim analysis of an ongoing safety study of FEBT in the treatment of cancer-related breakthrough pain (BTP). The study enrolled patients who were receiving stable doses of around-the-clock opioids for baseline pain and supplemental opioids for BTP. As of July 29, 2005, 129 participants (aged 24 to 95 years) constituted the safety population of the open-label phase, having consumed at least 1 dose of FEBT (100-800 μg).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
